Trichomonas Vaginalis Treatment Reduces Vaginal HIV-1 Shedding

Overview

Journal Sex Transm Dis

Specialty Infectious Diseases

Date 2008 Nov 15

PMID 19008776

Citations 89

Authors

Patricia Kissinger

Angela Amedee

Rebecca A Clark

Jeanne Dumestre

Katherine P Theall

Leann Myers

Michael E Hagensee

Thomas A Farley

David H Martin

Affiliations

Soon will be listed here.

Abstract

Background: Vaginal HIV-1 shedding has been associated with Trichomonas vaginalis (TV) infection and could play a role in HIV transmission. The purpose of the study was to examine if effective TV treatment reduces the presence of vaginal HIV-1 RNA.

Methods: TV+ women attending an HIV outpatient clinic in New Orleans, LA, who resolved infection (n = 58) and TV-negative controls (n = 92), matched on antiretroviral therapy (ART) were examined and interviewed at baseline, 1, and 3 months. TV status was tested by culture and the amount of cell free HIV-1 RNA in the vaginal fluids was determined by the Amplicor HIV-1 Monitor ultrasensitive assay.

Results: : Most women (81.3%) were black and the mean age was 37.5 (SD 8.7). At baseline, 46.0% had plasma HIV-1 RNA >/=10,000 copies/mL, 26.4% had CD4<200 cells/muL, 54.7% were taking ART, and only 26.0% had detectable HIV-1 RNA in their vaginal fluids. TV-positive women who were effectively treated for TV were less likely to shed HIV vaginally at 3-months post-treatment compared to baseline (R.R. 0.34, 95% CI: 0.12-0.92, P = 0.03), whereas there was no change for TV-negative women.

Conclusion: This study provides additional support that reducing TV infection among HIV-positive women may have an impact on the prevention of HIV transmission. Reasons for the delayed treatment effect and the effect on cervical shedding need further investigation.

Citing Articles

Effects of Schistosoma haematobium infection and treatment on the systemic and mucosal immune phenotype, gene expression and microbiome: A systematic review.

Mertelsmann A, Bowers S, Wright D, Maganga J, Mazigo H, Ndhlovu L PLoS Negl Trop Dis. 2024; 18(9):e0012456.

PMID: 39250522 PMC: 11412685. DOI: 10.1371/journal.pntd.0012456.

Assessment of and prevalence using a molecular Point of Care: Findings from a respondent driven sampling study among MSM.

Aitlhaj-Mhand R, Bellaji B, Jennane S, Remz C, Charof R, Khoudri I Infez Med. 2023; 31(2):234-242.

PMID: 37283639 PMC: 10241399. DOI: 10.53854/liim-3102-12.

Trichomoniasis.

Van Gerwen O, Opsteen S, Graves K, Muzny C Infect Dis Clin North Am. 2023; 37(2):245-265.

PMID: 37005163 PMC: 10713349. DOI: 10.1016/j.idc.2023.02.001.

Sexually Transmitted Infections in Pregnant People With Human Immunodeficiency Virus: Temporal Trends, Demographic Correlates, and Association With Preterm Birth.

Young M, Broadwell C, Kacanek D, Chadwick E, Jao J, Moscicki A Clin Infect Dis. 2022; 75(12):2211-2218.

PMID: 35486952 PMC: 10200300. DOI: 10.1093/cid/ciac321.

Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Kissinger P, Gaydos C, Sena A, McClelland R, Soper D, Evan Secor W Clin Infect Dis. 2022; 74(Suppl_2):S152-S161.

PMID: 35416973 PMC: 9006969. DOI: 10.1093/cid/ciac030.

References

Zeger S, Liang K . Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1):121-30. View

Rottingen J, Cameron D, Garnett G . A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?. Sex Transm Dis. 2001; 28(10):579-97. DOI: 10.1097/00007435-200110000-00005. View

Benki S, Mostad S, Richardson B, Mandaliya K, Kreiss J, Overbaugh J . Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. J Infect Dis. 2004; 189(12):2192-201. DOI: 10.1086/421298. View

Iversen A, Fugger L, Eugen-Olsen J, Balslev U, Jensen T, Wahl S . Cervical human immunodeficiency virus type 1 shedding is associated with genital beta-chemokine secretion. J Infect Dis. 1998; 178(5):1334-42. DOI: 10.1086/314433. View

McClelland R, Wang C, Mandaliya K, Overbaugh J, Reiner M, Panteleeff D . Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS. 2001; 15(1):105-10. DOI: 10.1097/00002030-200101050-00015. View

Seck K, Samb N, Tempesta S, Henzel D, Sow P, Mboup S . Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. Sex Transm Infect. 2001; 77(3):190-3. PMC: 1744303. DOI: 10.1136/sti.77.3.190. View

Sorvillo F, Smith L, Kerndt P, Ash L . Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis. 2001; 7(6):927-32. PMC: 2631893. DOI: 10.3201/eid0706.010603. View

Laga M, Alary M, Nzila N, Manoka A, Tuliza M, Behets F . Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet. 1994; 344(8917):246-8. DOI: 10.1016/s0140-6736(94)93005-8. View

Magnus M, Clark R, Myers L, Farley T, Kissinger P . Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity?. Sex Transm Dis. 2003; 30(11):839-43. DOI: 10.1097/01.OLQ.0000086609.95617.8D. View

10.

Ghys P, Fransen K, Diallo M, Ettiegne-Traore V, Coulibaly I, Yeboue K . The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire. AIDS. 1997; 11(12):F85-93. DOI: 10.1097/00002030-199712000-00001. View

11.

Theall K, Clark R, Powell A, Smith H, Kissinger P . Alcohol consumption, ART usage and high-risk sex among women infected with HIV. AIDS Behav. 2006; 11(2):205-15. DOI: 10.1007/s10461-006-9159-6. View

12.

McClelland R, Sangare L, Hassan W, Lavreys L, Mandaliya K, Kiarie J . Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007; 195(5):698-702. DOI: 10.1086/511278. View

13.

Van Der Pol B, Williams J, Orr D, Batteiger B, Fortenberry J . Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis. 2005; 192(12):2039-44. DOI: 10.1086/498217. View

14.

Patterson B, Landay A, Andersson J, Brown C, Behbahani H, Jiyamapa D . Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol. 1998; 153(2):481-90. PMC: 1852974. DOI: 10.1016/S0002-9440(10)65591-5. View

15.

Henin Y, Mandelbrot L, Henrion R, Pradinaud R, Coulaud J, Montagnier L . Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr (1988). 1993; 6(1):72-5. View

16.

Pudney J, Quayle A, Anderson D . Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod. 2005; 73(6):1253-63. DOI: 10.1095/biolreprod.105.043133. View

17.

Mostad S, Jackson S, Overbaugh J, Reilly M, Chohan B, Mandaliya K . Cervical and vaginal shedding of human immunodeficiency virus type 1-infected cells throughout the menstrual cycle. J Infect Dis. 1998; 178(4):983-91. DOI: 10.1086/515665. View

18.

Cauci S, Culhane J . Modulation of vaginal immune response among pregnant women with bacterial vaginosis by Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, and yeast. Am J Obstet Gynecol. 2007; 196(2):133.e1-7. DOI: 10.1016/j.ajog.2006.08.033. View

19.

Marrazzo J, Martin D . Management of women with cervicitis. Clin Infect Dis. 2007; 44 Suppl 3:S102-10. DOI: 10.1086/511423. View

20.

Uvin S, Caliendo A . Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women. Obstet Gynecol. 1997; 90(5):739-43. DOI: 10.1016/S0029-7844(97)00411-0. View